Penn Medicine Provider
Hematology, Medical Oncology
Kyle William Robinson, MD
4.9
(75)
Accepting new patients
Sees patients age 18 and up
Abramson Cancer Center Perelman 4th Floor West

About me

  • Associate Professor of Clinical Medicine (Hematology-Oncology)

Education and training

  • Medical School: Temple University School of Medicine
  • Residency: Temple University Hospital
  • Fellowship: Oregon Health & Science University

What my patients think about me

Average Rating
4.9

75 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

May 2025
5.0
5.0
very professional and knowledgeable
April 2025
5.0
5.0
smart , knowledgeable, concerned, effective and kind
February 2025
5.0
5.0
professional and knowledgeable
February 2025
5.0
5.0
the doctor remembers all my issues and ensures that i stay healthy.

Insurance accepted

My Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: On the medical staff, but does not have privileges to treat patients in the hospital.
Dr. Robinson is a Penn Medicine physician.

Qualifications and experience

My research

Barsouk A, Friedes C, Iocolano M, Doucette A, Cohen RB, Robinson KW, D'Avella CA, Marmarelis ME, Kosteva JA, Singh AP, Ciunci CA, Levin WP, Cengel KA, Bradley JD, Feigenberg SJ, Sun L, Aggarwal C, Langer CJ, Yegya-Raman N. Plunging Into the PACIFIC: Outcomes of Patients With Unresectable KRAS-Mutated Non-Small Cell Lung Cancer Following Definitive Chemoradiation and Durvalumab Consolidation , Clin Lung Cancer: 2024


Lin JK, Hearn CM, Getzen E, Long Q, Lee DC, Keaveny TM, Jayadevappa R, Robinson KW, Wong YN, Maxwell KN, Narayan V, Haas NB, Takvorian SU, Bikle DD, Chiang JM, Khan AN, Rajapakse CS, Morgans AK, Parikh RB. Validation of Biomechanical Computed Tomography for Fracture Risk Classification in Metastatic Hormone-sensitive Prostate Cancer , Eur Urol Oncol: 2023


Yegya-Raman N, Friedes C, Sun L, Iocolano M, Kim KN, Doucette A, Cohen RB, Robinson KW, Levin WP, Cengel KA, Lally B, Agarwal M, D'Avella CA, Marmarelis ME, Kosteva JA, Singh AP, Ciunci CA, Aggarwal C, Berman AT, Langer CJ, Feigenberg SJ. Utilization and Factors Precluding Receipt of Checkpoint Inhibitor Consolidation for Stage III NSCLC in a Large US Academic Health System , Clin Lung Cancer: 2023


Nickols NG, Mi Z, DeMatt E, Biswas K, Clise CE, Huggins JT, Maraka S, Ambrogini E, Mirsaeidi MS, Levin ER, Becker DJ, Makarov DV, Adorno Febles V, Belligund PM, Al-Ajam M, Muthiah MP, Montgomery RB, Robinson KW, Wong YN, Bedimo RJ, Villareal RC, Aguayo SM, Schoen MW, Goetz MB, Graber CJ, Bhattacharya D, Soo Hoo G, Orshansky G, Norman LE, Tran S, Ghayouri L, Tsai S, Geelhoed M, Rettig MB. Effect of Androgen Suppression on Clinical Outcomes in Hospitalized Men With COVID-19: The HITCH Randomized Clinical Trial , JAMA Netw Open, 5: 2022,e227852


Landsburg DJ, Nasta SD, Gerson JN, Svoboda J, Chong EA, Schuster SJ, Barta SK, Robinson KW, Hughes ME. Time-to-response for patients with relapsed/refractory diffuse large B cell and high grade B cell lymphoma treated with polatuzumab-based therapy , Leuk Lymphoma, 63(1): 2022,243-246


Parikh RB, Gallo JJ, Wong YN, Robinson KW, Cashy JP, Narayan V, Jayadevappa R, Chhatre S. Long-term depression incidence and associated mortality among African American and White prostate cancer survivors , Cancer, 127: 2021,3476-3485


Sun L, Parikh RB, Hubbard RA, Cashy J, Takvorian SU, Vaughn DJ, Robinson KW, Narayan V, Ky B. Assessment and Management of Cardiovascular Risk Factors Among US Veterans With Prostate Cancer , JAMA Netw Open, 4: 2021,e210070


Ravi B Parikh, Kyle W Robinson, Sumedha Chhatre, Elina Medvedeva, John P Cashy, Shika Veera, Joshua M Bauml, Tito Fojo, Amol S Navathe, S Bruce Malkowicz, Ronac Mamtani, Ravishankar Jayadevappa. Comparison by Race of Conservative Management for Low-Risk and Intermediate-Risk Prostate Cancers in Veterans From 2004 to 2018 , JAMA Netw Open , 3(9): 2020,e2018318.


Brandon H. Tieu, Mehee Choi, Kyle Robinson, Charles R. Thomas, Jr Other Thoracic Malignancies , The American Cancer Society's Oncology in Practice: Clinical Management: 2018


Robinson KW, Sandler AB EGFR Tyrosine Kinase Inhibitors: Difference in Efficacy and Resistance , Current Oncology Reports, 15(4): 2013,396-404